Fate Therapeutics Inc (FATE) Event Aug. 03, 2022, 20:03 UTC 17 1 comments (10% Negative) FATE THERAPEUTICS, INC. (FATE) Reports Q3 2022 Financial Results Comment Full text
Personalis Inc (PSNL) Event Aug. 03, 2022, 20:01 UTC 17 1 comments (30% Negative) Personalis, Inc. (PSNL) Reports Q3 2022 Financial Results Comment Full text
Spectrum Pharmaceuticals Inc (was acquised by Assertio Holdings, Inc (NASDAQ:ASRT) on 31/07/2023) (SPPI) Event Aug. 03, 2022, 14:17 UTC 18 1 comments (99% Neutral) SPECTRUM PHARMACEUTICALS INC (SPPI) Provides Business Update Comment Full text
Geron Corporation Inc (GERN) Event Aug. 03, 2022, 13:32 UTC 100 0 comments Geron - Wedbush PacGrow Healthcare Conference 2022 Comment Full text
Landos Biopharma Inc (was acquired by AbbVie Inc. (NYSE: ABBV) on 25/03/2024) (LABP) Event Aug. 03, 2022, 12:30 UTC 18 1 comments (90% Positive) Landos Biopharma, Inc. (LABP) Announces Enrollment Update for milestone Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment Comment Full text
Morphic Therapeutic (MORF) Event Aug. 03, 2022, 12:05 UTC 16 1 comments (30% Negative) Morphic Holding, Inc. (MORF) Reports Q3 2022 Financial Results Comment Full text
Pacira BioSciences Inc (PCRX) Event Aug. 03, 2022, 12:02 UTC 16 1 comments (10% Negative) PACIRA BIOSCIENCES, INC. (PCRX) Reports Q3 2022 Financial Results Comment Full text
Poseida Therapeutics (PSTX) Event Aug. 03, 2022, 11:36 UTC 16 1 comments (19% Negative) Poseida Therapeutics, Inc. (PSTX) Announces Delay in million Trials for multiple myeloma Due to Regulatory Process, Manufacturing Considerations, Efficacy Assessment Comment Full text
Kiniksa Pharmaceuticals (KNSA) Event Aug. 03, 2022, 11:35 UTC 16 1 comments (10% Negative) Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 2022 Financial Results Comment Full text
Seres Therapeutics Inc (MCRB) Event Aug. 03, 2022, 11:15 UTC 16 1 comments (30% Negative) SERES THERAPEUTICS, INC. (MCRB) Reports Q3 2022 Financial Results Comment Full text